<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25054756</article-id>
      <article-id pub-id-type="pmc">4148283</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20143013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The use of ustekinumab in a patient with severe psoriasis and
positive HBV serology<sup><xref ref-type="fn" rid="fn01">*</xref></sup>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Steglich</surname>
            <given-names>Raquel Bissacotti</given-names>
          </name>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meneghello</surname>
            <given-names>Luana Pizarro</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Carvalho</surname>
            <given-names>Andr&#xE9; Vicente Esteves</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheinquer</surname>
            <given-names>Hugo</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muller</surname>
            <given-names>Fernanda Melo</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reginatto</surname>
            <given-names>Fl&#xE1;via Pereira</given-names>
          </name>
        </contrib>
        <aff>Complexo Hospitalar Santa Casa de Miseric&#xF3;rdia de Porto Alegre - Porto Alegre
(RS), Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Raquel Bissacotti Steglich, Rua Ricardo Landmann,
639, 89218-200 - Joinville - SC, Brazil. E-mail:
<email>raquelsteglich@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>4</issue>
      <fpage>652</fpage>
      <lpage>654</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to
2% of the world's population. Immunobiological medications are prescribed for
certain patients with severe forms of psoriasis, however, these drugs increase
the risk of reactivation of viral diseases such as hepatitis B. We report the
case of a patient with severe psoriasis with positive serology for the Hepatitis
B virus, who received ustekinumab (a human monoclonal antibody against
interleukin 12 and 23). In this patient, the use of ustekinumab did not
reactivate the Hepatitis B virus. Given the high prevalence of chronic viral
infections in patients who are candidates for biologic therapy, as well as the
potential for reactivate chronic viral illness, randomized controlled studies
are needed to assess the risks and benefits of such therapy in these
populations.</p>
      </abstract>
      <kwd-group>
        <kwd>Hepatitis B</kwd>
        <kwd>Hepatitis B virus</kwd>
        <kwd>Psoriasis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Psoriasis is a chronic inflammatory, immunemediated, systemic disease that afflicts
1% to 2% of the world's population.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>Treatments with biologics have been shown to improve the lives of many patients with
psoriasis.<sup><xref rid="r03" ref-type="bibr">3</xref></sup> Issues
concerning the potential risks of reactivating the hepatitis B virus (HBV) arise
when the use of biologic agents is imperative in patients with concurrent psoriasis
and HBV infection.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> The
reactivation of HBV during immunosuppressive therapy has even been reported in HBsAg
negative patients, who are anti-HBc positive with or without anti-HBs
antibodies.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>We report the case of a 53-year-old Brazilian black man who presented with a 27-year
history of recalcitrant severe psoriasis. Over the last 14 years, he had been
treated at a specialized dermatology department, where he received standard topical
and systemic treatment for psoriasis. PUVA, methotrexate, cyclosporine and acitretin
had to be discontinued because of inefficacy, intolerance or toxicity. He had a
history of pulmonary tuberculosis, which was duly treated 29 years ago. With this
background, a PASI score of 61.2, BSA 81%, and a poor quality of life, treatment
with ustekinumab was indicated, a fully human monoclonal antibody directed against
interleukin 12 (IL-12) and interleukin 23 (IL-23) (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Severe psoriasis and a poor quality of life in a patient with history of
pulmonary tuberculosis and positive HBV serology</p>
        </caption>
        <graphic xlink:href="abd-89-04-0652-g01"/>
      </fig>
      <p>Before treatment, HBV serology revealed the following results: anti-HBc IgG
positivity; low titer anti-HBs (2 mIU/ml), and negativity for anti-HBc IgM, HBsAg,
HBeAg and anti-HBe. The viral load was undetectable for HBV. Anti-HCV and anti-HIV
were also negative. There were no respiratory symptoms, while the chest X-ray and
Mantoux test were normal.</p>
      <p>The patient was prophylactically treated with isoniazid for 6 months before starting
the biologic treatment, and vaccinated against HBV, achieving anti-HBs positivity.
Lamivudine (75mg per day) was started on the same day as the ustekinumab induction
dose (45mg), lasting throughout the whole treatment period.</p>
      <p>Lesions improved significantly 3 weeks after the first dose of ustekinumab (PASI 18 /
BSA 47%). The patient responded excellently, maintaining PASI 3.8 / BSA 13%, normal
liver tests, with no adverse effects in a three-year follow-up (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>The patient obtained excellent response with anti-IL12/23 and lamivudine in a
two year follow-up with no adverse effects</p>
        </caption>
        <graphic xlink:href="abd-89-04-0652-g02"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>There are several reports of HBV reactivation after immune suppression. It is known
that the HBV integrates with the host genome and can remain indefinitely in the
nucleus of hepatocytes in the form of ccc-DNA. This material serves as a genomic
template for HBV replication and sets the stage for future HBV reactivation whenever
immunologic control of the virus is disrupted.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> The drugs most associated with HBV recurrence are those used
either in the treatment of hemato-oncological malignancies, or the control of
autoimmune diseases such as rituximab (anti-CD20) and tumor necrosis factor-&#x3B1;
antagonists.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>The prophylactic use of antiviral drugs like lamivudine during and after anti-TNF-&#x3B1;
and ustekinumab therapy is an important issue that has yet to be properly defined in
patients with HBV infection. Lamivudine is a reverse transcriptase inhibitor
commonly prescribed in patients with chronic HBV infection receiving cancer
chemotherapy or undergoing transplantation.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> Antiviral prophylaxis appears to minimize the risk of viral
reactivation in patients undergoing biologics therapy with concurrent psoriasis and
HBV. However, some medical entities do not reimburse anti-viral therapy for
non-cancer patients receiving biologics.<sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>We presented a patient that probably developed immunity to HBV following contact with
this virus, although anti-HBs titer was low. The use of ustekinumab did not
reactivate HBV, possibly because his HBsAg was negative, his anti-HBs titers
increased before treatment and an antiviral with activity against HBV replication
was initiated concomitantly.</p>
      <p>Recently, reports were made of 2 cases of acute hepatitis B infection in patients
treated with ustekinumab. Although the serological profiles of both patients
corroborate the definition of a typical acute infection, a potential reactivation of
an undetected, latent infection cannot be discounted in either case.<sup><xref rid="r07" ref-type="bibr">7</xref></sup> Some observations suggest that
ustekinumab may effectively neutralize IL-12/23 mediated functional responses,
without affecting immune responses stimulated through other cytokines or cellular
activities. While it is not possible to generate definitive conclusions about the
roles of IL-12/23 in host immunity toward HBV based on these 2 cases, ustekinumab
did not appear to impact acute hepatitis B immunity.<sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>Given the high prevalence of chronic viral infections in patients who are candidates
for therapy with biologic products, as well as the potential for these agents to
reactivate chronic viral illness, randomized controlled studies are needed to assess
the risks and benefits of such therapy in these populations, whether one anti-TNFa
agent is safer than the others, and when or if to initiate antiviral
therapy.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup> It remains
uncertain whether ustekinumab therapy affects the risk of HBV.<sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>Nevertheless, close surveillance of the patients' HBV status before and during
therapy with any biologic agent is strongly recommended. In addition, laboratory
tests are fundamental in monitoring liver function for early detection of viral
reactivation.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at the Complexo Hospitalar Santa Casa de Miseric&#xF3;rdia de Porto
Alegre - Porto Alegre (RS), Brazil.</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Steglich RB, Meneghello LP, Carvalho AVE, Cheinquer H,
M&#xFC;ller FM, Reginatto FP. The use of ustekinumab in a patient with severe
psoriasis and positive HBV serology. An Bras Dermatol. 2014;89(4):652-4.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abramson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Menter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Perrillo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis, hepatitis B, and the tumor necrosis factor-alpha
inhibitory agents: a review and recommendations for
management</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2012</year>
          <volume>67</volume>
          <fpage>1349</fpage>
          <lpage>1361</lpage>
          <pub-id pub-id-type="pmid">22727462</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arruda</surname>
              <given-names>LHF</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>GAM</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>MDF</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis</article-title>
          <source>An bras Dermatol,</source>
          <year>2001</year>
          <volume>76</volume>
          <fpage>141</fpage>
          <lpage>167</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uhlenhake</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Mehregan</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Ustekinumab: differential use in psoriasis</article-title>
          <source>Clin Cosmet Investig Dermatol</source>
          <year>2011</year>
          <volume>4</volume>
          <fpage>93</fpage>
          <lpage>99</lpage>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fotiadou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lazaridou</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ioannides</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Safety of anti-tumour necrosis factor-a agents in psoriasis
patients who were chronic hepatitis B carriers: a retrospective report of
seven patients and brief review of the literature</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2011</year>
          <volume>25</volume>
          <fpage>471</fpage>
          <lpage>474</lpage>
          <pub-id pub-id-type="pmid">20561122</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koskinas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tampaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Doumba</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Rallis</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis B virus reactivation during therapy with ustekinumab
for psoriasis in an HBsAg negative anti-HBs positive patient</article-title>
          <source>Br J Dermatol</source>
          <year>2013</year>
          <volume>168</volume>
          <fpage>679</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="pmid">23121260</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiu</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>TF</given-names>
            </name>
          </person-group>
          <article-title>The safety profile of ustekinumab in the treatment of patients
with psoriasis and concurrent hepatitis B or C</article-title>
          <source>Br J Dermatol</source>
          <year>2013</year>
          <volume>169</volume>
          <fpage>1295</fpage>
          <lpage>1303</lpage>
          <pub-id pub-id-type="pmid">23746170</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Opel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Economidi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wasfi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mistry</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vergou</surname>
              <given-names>T</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Two cases of Hepatitis B in patients with moderate to severe
psoriasis treated with Ustekinumab</article-title>
          <source>J Drugs Dermatol</source>
          <year>2012</year>
          <volume>11</volume>
          <fpage>1498</fpage>
          <lpage>1501</lpage>
          <pub-id pub-id-type="pmid">23377523</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calabrese</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Zein</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Vassilopoulos</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Safety of antitumour necrosis factor (anti-TNF) therapy in
patients with chronic viral infections: hepatitis C, hepatitis B, and HIV
infection</article-title>
          <source>Ann Rheum Dis</source>
          <year>2004</year>
          <volume>63</volume>
          <fpage>ii18</fpage>
          <lpage>ii24</lpage>
          <pub-id pub-id-type="pmid">15479865</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
